PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
ED  - Schlumberger, Martin
TI  - Lenvatinib Improves Progression-Free Survival in Refractory Thyroid Cancer
DP  - 2014 Aug 01
TA  - MD Conference Express
PG  - 13--14
VI  - 14
IP  - 14
4099  - http://mdc.sagepub.com/content/14/14/13.short
4100  - http://mdc.sagepub.com/content/14/14/13.full
AB  - This article presents outcomes from A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (SELECT; NCT01321554) [Schlumberger M et al. J Clin Oncol 2014]. The trial compared the progression-free survival (of subjects with 131I-refractory differentiated thyroid cancer who were treated with lenvatinib versus placebo.